Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 and CD22 targeted CAR-T cells (Gracell Biotechnologies)
- Development stage
- Unknown
- Lead developer
- Gracell Biotechnologies
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19 and CD22 targeted CAR-T cells refers to a dual-antigen chimeric antigen receptor (CAR) T-cell therapy designed to treat B-cell malignancies. By targeting both CD19 and CD22, these cells aim to reduce the risk of relapse caused by antigen escape, which occurs when cancer cells lose the expression of a single target (like CD19) under selective pressure. The specific program described in the context utilizes the FasT CAR-T manufacturing platform, developed by Gracell Biotechnologies (now part of AstraZeneca), which significantly reduces the production time to approximately 24 hours while preserving the T-cell stemness and proliferative capacity. This approach is being investigated for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) and acute lymphoblastic leukemia (ALL).
- Other names
- CD19/CD22 dual-targeted CAR-T cellsCD19/CD22 FasT CAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CD19 and CD22 targeted CAR-T cells (Gracell Biotechnologies).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 and CD22 targeted CAR-T cells (Gracell Biotechnologies).